Elmiron and Abnormal posturing - a phase IV clinical study of FDA data
Summary:
We study 10,218 people who take Elmiron (pentosan polysulfate sodium) or have Abnormal posturing. No report of Abnormal posturing is found in people who take Elmiron.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Elmiron?
Elmiron has active ingredients of pentosan polysulfate sodium. It is often used in interstitial cystitis (ic). eHealthMe is studying from 10,215 Elmiron users. Check the latest studies of Elmiron.
What is Abnormal Posturing?
Abnormal posturing: no further information found. Check the latest studies of Abnormal posturing.
No report is found.
Do you take Elmiron and have Abnormal posturing?
- Check whether Abnormal posturing is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Elmiron:
- Elmiron (10,215 reports)
Abnormal posturing treatments and more:
- Abnormal posturing (3 reports)
How severe was Abnormal posturing and when was it recovered:
Expand to all the drugs that have ingredients of pentosan polysulfate sodium:
Browse all side effects of Elmiron:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Abnormal posturing:
Browse all the conditions that are associated with Abnormal posturing:
How the study uses the data?
The study uses data from the FDA. It is based on pentosan polysulfate sodium (the active ingredients of Elmiron) and Elmiron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Aloxi cause Dizziness? - a second ago
- Metastatic Renal Cell Carcinoma and Cardiopulmonary Failure - 10 seconds ago
- Could Vitamin K1 cause Appetite - Decreased? - 11 seconds ago
- Could Vitamin K1 cause Appetite Decreased? - 11 seconds ago
- Drug interactions of Qvar and Epzicom - 12 seconds ago
- International Normalised Ratio Decreased and Head Injury - 13 seconds ago
- Drug interactions of Atarax and Pravastatin Sodium - 17 seconds ago
- Drug interactions of Desyrel and Atenolol - 29 seconds ago
- Could Peppermint Oil cause Dizziness? - 36 seconds ago
- Gastric Ulcer and Type 1 Diabetes - 41 seconds ago